LAWRENCE, Mass., July 3, 2014 /PRNewswire/ -- In honor of
Independence Day, NxStage Medical,
Inc. (NASDAQ: NXTM), a leading manufacturer of innovative
dialysis products, joins patients across the nation in celebrating
the freedom and flexibility they have reclaimed with home
hemodialysis (HHD) using the NxStage® System
One™.
"After I was injured in the line of duty, my kidneys failed and
I was stuck in-center with no hope of coming out," said veteran and
businessman, Rod Jones of
North Carolina. "I felt trapped,
dependent and constantly exhausted because of my treatment. Now I
am a new man thanks to more frequent home hemodialysis and NxStage
– independent and free to do anything I want." Jones works
full-time and is currently studying to obtain his sixth degree in
electrical engineering.
Walfred Lopez, a community
activist and NxStage patient in Los
Angeles, explains that more frequent HHD has helped him
regain his independence and focus on community activism serving
full-time as a Community Health Promoter and a board member of the
Binational Health Week. "Independence means being closer to my
dreams, doing what I like, and being an active advocate and
counselor for the Hispanic community – similar to the way I lived
my life before my kidneys failed," said Lopez.
Alphonso Jefferson, a military
veteran from Virginia, has the
freedom to enjoy athletics and an active lifestyle. Jefferson, who
began using the NxStage System One in 2009, has traveled
extensively across the United
States, and even participates annually in a 220-mile bike
race. "The flexibility of the System One has allowed me to travel
across the country with my nephew who is a college football
recruit. NxStage has given me the opportunity to help my nephew
achieve his dream of playing college football," said Jefferson.
"For many, an ESRD diagnosis is terrifying," said NxStage
President Joe Turk. "Hearing
directly from our patients that home hemodialysis helps them regain
a sense of independence and have quality of life, is very
rewarding. We encourage patients to embrace this flexibility and
join them in celebrating their ability to live freely."
Beginning July 16th,
NxStage will kick off its Freedom Tour. The Tour is designed to
increase patient awareness of home hemodialysis and consists of a
NxStage patient along with her care partner, making scheduled stops
at dialysis centers in nine cities along the East Coast. The
NxStage patient will speak with other dialysis patients about the
benefits of more frequent home hemodialysis and perform
demonstrations using the NxStage System One.
Watch and hear how other NxStage patients are celebrating their
independence by visiting
http://ww2.nxstage.com/Independence.html. To learn more
about NxStage and the System One, visit www.nxstage.com or
join the conversation on Facebook at facebook.com/NxStage,
Twitter
at @NxStage and YouTube at youtube.com/user/NxStage.
Despite the health benefits that more frequent home
hemodialysis may provide to those with chronic kidney disease, this
form of therapy is not for everyone. The reported benefits of home
hemodialysis may not be experienced by all patients. The risks
associated with hemodialysis treatments in any environment include,
but are not limited to, high blood pressure, fluid overload, low
blood pressure, heart-related issues, and vascular access
complications. The medical devices used in hemodialysis therapies
may add additional risks including air entering the bloodstream and
blood loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
About the NxStage System One
The NxStage System One is the first and only truly portable
hemodialysis system cleared for home use by the U.S. Food &
Drug Administration (FDA). Its simplicity and revolutionary size
(just over a foot tall) are intended to allow convenient use in
patients' homes and give patients the freedom to travel with their
therapy. When combined with the NxStage Pureflow SL Dialysis
Preparation System, patients are able to further simplify, using
ordinary tap water to create dialysis fluid. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs - at home
or on vacation and at a medically appropriate treatment frequency.
http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq:
NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. For more information on NxStage and
its products, please visit the Company's website at
www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including the Quarterly Report on Form 10-Q for the
quarter ended March 31, 2014. NxStage
is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media contact:
Meredith D'Agostino
mdagostino@451marketing.com
617-986-0216
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
SOURCE NxStage Medical, Inc.